Standout Papers
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (2016)
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study (2017)
Immediate Impact
1 by Nobel laureates 10 from Science/Nature 71 standout
Citing Papers
A vision–language foundation model for precision oncology
2025 StandoutNature
Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
Works of Steven Powell being referenced
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
2020
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Steven Powell | 2531 | 1556 | 406 | 589 | 90 | 3.5k | |
| Shaodong Hong | 2807 | 1804 | 606 | 531 | 125 | 3.8k | |
| Joshua Bauml | 2198 | 1620 | 503 | 369 | 137 | 3.1k | |
| Kathryn A. Gold | 2092 | 1794 | 896 | 294 | 99 | 3.4k | |
| Sana D. Karam | 1595 | 854 | 648 | 585 | 159 | 3.2k | |
| Paul B. Romesser | 919 | 831 | 633 | 324 | 110 | 2.6k | |
| Anne O’Neill | 1802 | 802 | 490 | 614 | 89 | 3.5k | |
| Jill Gilbert | 2081 | 1166 | 1038 | 627 | 91 | 4.4k | |
| Jean Trédaniel | 1198 | 958 | 555 | 277 | 108 | 2.5k | |
| Ravit Geva | 4002 | 1572 | 801 | 1174 | 133 | 5.2k | |
| Jean‐Pascal Machiels | 1521 | 1108 | 781 | 327 | 135 | 3.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...